04/18/2026
President Trump signs an executive order on Psychedelic Drugs. After conversations with Joe Rogan.
The executive order signed by President Trump on April 18, 2026, primarily focuses on accelerating federal research and expanding patient access to psychedelic treatments rather than immediate broad legalization. While psychedelics like ibogaine, psilocybin, M**A, and L*D remain federally illegal Schedule I substances, the order introduces several legal pathways to change their status and accessibility.
PBS
+3
Key Legal and Regulatory Changes
* FDA Fast-Tracking: The order directs the Food and Drug Administration (FDA) to expedite the review of psychedelics that have received "Breakthrough Therapy" designations. This could lead to formal reclassification or approval as soon as the summer of 2026.
* Right to Try Expansion: It instructs the FDA and the Drug Enforcement Administration (DEA) to establish a legal pathway for eligible patients—particularly those with treatment-resistant mental illnesses—to access investigational psychedelics under the Right to Try Act.
* Federal Funding for Research: The order allocates $50 million in federal funds specifically for research into ibogaine to treat conditions like PTSD and opioid addiction.
* Priority Vouchers: To encourage development, the FDA is directed to provide National Priority Vouchers to companies developing appropriate psychedelic drugs, which can be used to speed up the review of future drug applications.
*
* The White House (.gov)� +5
Current Legal Status
Despite these reforms, the current legal landscape remains complex:
* Federal Prohibition: Most classic psychedelics remain on Schedule I of the Controlled Substances Act, meaning they are federally illegal to possess or distribute outside of approved research.
* State-Level Variation: States like Oregon and Colorado have already established their own legal frameworks for psychedelic therapy, which operate independently of this federal order.
* No Immediate Recreational Legalization: The order does not legalize recreational use; it is strictly focused on clinical research and medical treatment for serious mental health conditions
